



LYTHAM
PARTNERS

INVESTOR SELECT CONFERENCE

BY INVESTORS. FOR INVESTORS.

JANUARY 31, 2023

[LYTHAMPARTNERS.COM/VIRTUAL](https://lythampartners.com/virtual)



VIRTUAL CONNECTIONS. REAL VALUE.

Lytham Partners presents the Investor Select Conference, an exclusive event created By Investors, For Investors. This virtual conference will feature companies nominated and selected by institutional investors for a series of company presentations and valuable 1x1 meetings.

REQUEST 1X1 MEETINGS

ABOUT LYTHAM PARTNERS

Lytham Partners is one of the country's leading investor relations firms. With more than two decades of Corporate Access experience, we have built one of the industry's most diverse and effective platforms for connecting small cap companies with high quality and focused institutional investors.

ABOUT OUR CONFERENCES

The mission of the Lytham Partners Investor Conference Series is to create value for small cap companies through virtual connections with high-quality institutional investors. Our conference series has featured more than 200 companies from various industries including healthcare & pharma, consumer, technology, industrials & special situations, clean tech, and financial services.

CONNECT WITH US

We are excited to connect with our audience and share this virtual event online. Follow Lytham Partners IR on LinkedIn and [click here](#) to RSVP to our event page to stay updated on the latest conference news.



#lythamselect2023



PARTICIPATING COMPANIES

P = Presenting Company (webcasts linked below)

BASIC MATERIALS

- P** [Arienne Phosphate \(TSXV: DAN / PINK: DRRSF\)](#)
Northern Technologies International Corporation
(NASDAQ: NTIC)
Vox Royalty Corp. (TSXV: VOX / OTCQX: VOXCF)

HEALTHCARE

- P** [Acasti Pharma \(NASDAQ: ACST / TSXV: ACST\)](#)
Aurora Spine Corp. (TSXV: ASG / OTCQB: ASAPF)
- P** [Aytu BioPharma, Inc. \(NASDAQ: AYTU\)](#)
Cosmos Holdings, Inc. (NASDAQ: COSM)
Delcath Systems (NASDAQ: DCTH)
Immucell Corp. (NASDAQ: ICCG)
INVO Bioscience (NASDAQ: INVO)
- P** [Jaguar Health, Inc. \(NASDAQ: JAGX\)](#)
LifeMD, Inc. (NASDAQ: LFMD)
- P** [Mannkind Corporation \(NASDAQ: MNKD\)](#)
OpSens Inc. (TSX: OPS / OTCQX: OPSSF)
Perimeter Medical Imaging (TSXV: PINK / PINK: PYNKF)
PetVivo Holdings Inc. (NASDAQ: PETV)
Quipt Home Medical (NASDAQ: QIPT / TSXV: QIPT)
- P** [Reliq Health Technologies Inc. \(TSXV: RHT / PINK: ROHTF\)](#)
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH)
Scientific Industries, Inc. (OTCQB: SCND)
Sensus Healthcare (NASDAQ: SRTS)
- P** [Shuttle Pharmaceuticals, Inc. \(NASDAQ: SHPH\)](#)
- P** [SOBR Safe, Inc. \(NASDAQ: SOBR\)](#)
- P** [Spok Holdings, Inc. \(NASDAQ: SPOK\)](#)
Trellus Health plc (AIM: TRLS)
VolitionRx Limited (NYSE American: VNRX)
- P** [Zomedica \(NYSE American: ZOM\)](#)

CONSUMER

- Aquafil SpA (OTCQX: ECNLF/ Euronext Star Milan: ECNL)
- Charles & Colvard (NASDAQ: CTHR)
- Galaxy Gaming (OTCQB: GLXZ)

FINTECH

- AppTech Payments Corp. (NASDAQ: APCX)
- Mogo Inc. (NASDAQ: MOGO / TSX: MOGO)

INDUSTRIALS

- P** [Limbach Holdings, Inc. \(NASDAQ: LMB\)](#)
LiqTech International, Inc. (NASDAQ: LIQT)
S&W Seed Company (NASDAQ: SANW)
- P** [SenesTech Inc. \(NASDAQ: SNES\)](#)

TECHNOLOGY

- Dotz Nano (ASX: DTZ / PINK: DTZZF)
- P** [GSE Systems Inc. \(NASDAQ: GVP\)](#)
HUB Security (TASE: HUB)
KVH Industries, Inc. (NASDAQ: KVHI)
- P** [LiveWorld, Inc. \(PINK: LVWD\)](#)
OneSoft Solutions Inc. (TSXV: OSS / OTCQB: OSSIF)
One Stop System (NASDAQ: OSS)
- P** [Precision Optics Corporation \(NASDAQ: POCL\)](#)
Zoomd Technologies (TSXV: ZOMD / OTC: ZMDTF)

This list has been updated as of January 27, 2023. Participation subject to change.

CONTACT US!

For more information on our Investor Select Conference, please call 602.889.9700 or email us at conference@lythampartners.com

COMPANY PROFILES

Market Cap data (\$USD) updated as of 1.24.23

ACASTI PHARMA (NASDAQ: ACST / TSXV: ACST)

Healthcare | Market Cap: \$36M

Acasti is a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Acasti's novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery—all which could help to increase treatment compliance and improve patient outcomes. Acasti's three lead clinical assets have each been granted Orphan Drug Designation by the U.S. FDA, which provide the assets with seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Acasti's lead clinical assets target underserved orphan diseases: (i) GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTX-102, an oral mucosal spray targeting Ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily affects children, causing severe disability, and for which no treatment currently exists; and (iii) GTX-101, a topical spray targeting Postherpetic Neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years.

APPTech PAYMENTS CORP. (NASDAQ: APCX)

FinTech | Market Cap: \$62M

AppTech Payments Corp., is a financial technology company, provides electronic payment processing technologies and merchant services in the United States. Its merchant services offer financial processing for businesses to accept cashless payments, such as credit cards, automatic clearing house, and wireless payments. The company's merchant services software offers integrated solutions, such as data encryption, payment tokenization, issuing banking authorization, and the creation of white-label and merchant-specific mobile applications for friction less digital and mobile payment acceptance, including acceptance of alternative payment methods, as well as multi-use case, multi-channel, API-driven, and account-based issuer processing for card, digital tokens, and payment transfer transactions. It is developing mobile payment platform relies on SMS text messaging.

AQUAFIL SPA (OTCQX: ECNLF / Euronext Star Milan: ECNL)

Consumer | Market Cap: \$337M

A leading manufacturer Since 1965, the Aquafil Group has been a pioneer of the circular economy and a landmark in terms of quality and product innovation for Italy and the globe. We primarily manufacture Nylon 6 fibers and polymers but also Nylon 6.6 and Dryarn. Our flagship product is ECONYL® nylon, which revolutionizes the world of synthetic fibers through a closed-loop model. Today, Aquafil remains a leader in the research of new production systems for sustainable development.

ARIANNE PHOSPHATE (TSXV: DAN / PINK: DRRSF)

Basic Materials | Market Cap: \$45M

Arianne Phosphate ("Arianne Phosphate Inc.") (www.arianne-inc.com) is developing the Lac à Paul phosphate deposits located approximately 200 km north of the Saguenay/Lac St. Jean area of Quebec, Canada. These deposits will produce a high-quality igneous apatite concentrate grading 39% P2O5 with little or no contaminants (Feasibility Study released in 2013). The Company has 185,464,469 shares outstanding.

AURORA SPINE CORP. (TSXV: ASG / OTCQB: ASAPF)

Healthcare | Market Cap: \$24M

Aurora Spine Corporation (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes. Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.

AYTU BIOPHARMA, INC. (NASDAQ: AYTU)

Healthcare | Market Cap: \$12M

Aytu BioPharma is a pharmaceutical company with a portfolio of commercial prescription therapeutics and consumer health products, and a growing therapeutics pipeline focused on treating rare, pediatric-onset disorders. The company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines in various formulations for infants and children with fluoride deficiency. Aytu is also building a therapeutic pipeline, which includes AR101 (enzastaurin), a PKC inhibitor in development for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disease typically diagnosed in childhood resulting in high morbidity and a significantly shortened lifespan, and for which there are no currently approved treatments. AR101 has received Orphan Drug designation and Fast Track designation from the U.S. Food and Drug Administration and has received Orphan Drug designation from the European Commission. Aytu is also researching and advancing the development of the Heallight ultraviolet light A (UVA) endotracheal catheter, a patented, investigational medical device with potential application in the treatment of severe, difficult-to-treat respiratory infections.

COMPANY PROFILES

Market Cap data (\$USD) updated as of 1.24.23

CHARLES & COLVARD (NASDAQ: CTHR)

Consumer | Market Cap: \$27M

Charles & Colvard, Ltd. (Nasdaq: CTHR) believes fine jewelry can be accessible, beautiful and conscientious. Charles & Colvard is the original creator of lab grown moissanite, a rare gemstone formed from silicon carbide. The Company brings revolutionary gemstones and jewelry to market through its pinnacle Forever One™ moissanite brand and its premium Caydia® lab grown diamond brand. Consumers seek Charles & Colvard fashion, bridal and fine jewelry because of its exceptional quality, incredible value and shared beliefs in environmental and social responsibility. Charles & Colvard was founded in 1995 and is based in North Carolina's Research Triangle Park region. For more information, please visit www.charlesandcolvard.com.

COSMOS HOLDINGS, INC. (NASDAQ: COSM)

Healthcare | Market Cap: \$49M

Cosmos Health is an international healthcare engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranean". Cosmos Holdings Inc. is operating in the pharmaceutical sector as well, through the provision of a broad line of branded generics and OTC medications. In addition, the group is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Holdings Inc. is strategically focusing on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products.

DEL CATH SYSTEMS (NASDAQ: DCTH)

Healthcare | Market Cap: \$38M

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA). In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

DOTZ NANO (ASX: DTZ / PINK: DTZZF)

Technology | Market Cap: \$78M

Dotz is a technology leader in research, production and marketing of graphene quantum dots. Its unique products ValiDotz, BioDotz, Fluorensic and InSpec are exceptional solutions for numerous applications, such as: bio-imaging, liquids tagging, lubricants and DEF authentication, diagnostic, polymers tagging, anti-counterfeiting and brand protection.

GALAXY GAMING (OTCQB: GLXZ)

Consumer | Market Cap: \$75M

Galaxy Gaming is the industry's most customer-centric partner. Omnichannel table games experts delivering innovative games and technologies proven to perform. Our mission is to enhance our clients' casino gaming operations and improve profitability, productivity, and security, while offering popular cutting-edge gaming entertainment content and technology to their players. Casino table game concepts and intellectual property associated with these games are typically protected by patents, trademarks, and copyrights. You will find our games placed in casinos in North America, the Caribbean, the British Isles, Europe, and Africa, as well as on cruise ships and on iGaming sites worldwide. Currently, we have an installed base of our products on over 6,000 gaming tables located in over 600 casinos, which positions us as the largest independent provider of proprietary casino table games in the world.

GSE SYSTEMS, INC. (NASDAQ: GVP)

Technology | Market Cap: \$16M

As a collective group, GSE Solutions leverages top skills, expertise, and technology to provide highly specialized solutions that allow customers to achieve the performance they imagine. Our experts deliver and support end-to-end training, engineering, compliance, simulation, and workforce solutions that help the power industry reduce risk and optimize plant operations. GSE is proven, with over four decades of experience, more than 1,100 installations, and hundreds of customers in over 50 countries spanning the globe. www.gses.com.

HUB SECURITY (TASE: HUB)

Technology | Market Cap: \$2M

(Announced Business Combination with Mount Rainier Acquisition Corp. (NASDAQ: RNER)) HUB Cyber Security (Israel) Limited ("HUB") was established in 2017 by veterans of the 8200 and 81 elite intelligence units of the Israeli Defense Forces. The company specializes in unique Cyber Security solutions protecting sensitive commercial and government information. The company debuted an advanced encrypted computing solution aimed at preventing hostile intrusions at the hardware level while introducing a novel set of data theft prevention solutions. HUB operates in over 30 countries and provides innovative cybersecurity computing appliances as well as a wide range of cybersecurity services worldwide.

IMMUCELL (NASDAQ: ICCC)

Healthcare | Market Cap: \$57M

ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics.

COMPANY PROFILES

Market Cap data (\$USD) updated as of 1.24.23

INVO BIOSCIENCE (NASDAQ: INVO)

Healthcare | Market Cap: \$6M

INVO Bioscience is a medical device company focused on creating simplified, affordable treatments for patients diagnosed with infertility. Our solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Their lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell® is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). INVO's mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care.

JAGUAR HEALTH, INC. (NASDAQ: JAGX)

Healthcare | Market Cap: \$780M

Jaguar Health, Inc. is a San Francisco, CA-based commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Animal Health is a tradename of Jaguar Health. Our wholly owned subsidiary, Napo Pharmaceuticals (Napo), focuses on developing and commercializing proprietary plant-based human pharmaceuticals for the global marketplace from plants or plant products used traditionally in rainforest areas. Napo's marketed drug Mytesi® (crofelemer 125 mg delayed-release tablets) is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. To date, this is the only oral plant-based botanical prescription medicine approved under the FDA's Botanical Guidance. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. Napo Therapeutics is initially focused on two key orphan target indications for crofelemer: Short bowel syndrome (SBS) with intestinal failure, and congenital diarrheal disorders (CDD). Jaguar Animal Health's Canalevia®-CAI (crofelemer delayed-release tablets) drug is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CAI is now available from multiple leading veterinary distributors in the U.S. to veterinarians. Crofelemer is a novel, first in class anti secretory agent which has a normalizing effect on electrolyte and fluid balance while acting locally in the gut, and this mechanism of action has the potential to benefit multiple disorders that cause gastrointestinal distress, including diarrhea and abdominal discomfort. Crofelemer is in development for additional possible human follow-on indications, including the management of diarrhea and abdominal discomfort in inflammatory bowel disease (IBD); diarrhea-predominant irritable bowel syndrome (IBS-D); and for idiopathic/functional diarrhea. A second-generation proprietary anti-secretory agent, NP-300 (lechlemer), is undergoing preclinical development for symptomatic relief and treatment of diarrhea in patients with acute infection from cholera. For more information about Jaguar Health, please visit <https://jaguar.health>. For more information about Napo Pharmaceuticals, visit www.napopharma.com.

KVH INDUSTRIES, INC. (NASDAQ: KVHI)

Technology | Market Cap: \$196M

KVH Industries, Inc., is a global leader in mobile connectivity systems, with innovative technology designed to enable a mobile world. A market leader in maritime VSAT, KVH designs, manufactures, and provides connectivity and content services globally. Founded in 1982, the company is based in Middletown, RI, with research, development, and manufacturing operations in Middletown, RI and more than a dozen offices around the globe.

LIFEMD, INC. (NASDAQ: LFMD)

Healthcare | Market Cap: \$60M

LifeMD is a 50-state direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized treatment for men's and women's health, allergy & asthma, and dermatological conditions. By leveraging its proprietary technology platform, 50-state affiliated medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to top-notch healthcare that is affordable to anyone. To learn more, go to LifeMD.com.

LIMBACH HOLDINGS, INC. (NASDAQ: LMB)

Industrials | Market Cap: \$131M

Limbach Holdings, Inc., (NASDAQ: LMB), with revenue of \$490.4 million in 2021, is an integrated building systems solutions firm whose expertise is the design, installation, management, service, and maintenance of HVAC, mechanical, electrical, plumbing and control systems. With well over 1,650 employees located across the United States, we have assembled a team of engineering, construction, maintenance, and technology experts to provide our Building Owner and General Contractor clients with systems that work while offering insights and outcomes that maximize the return on your investment.

LIQTECH INTERNATIONAL, INC. (NASDAQ: LIQT)

Industrials | Market Cap: \$20M

LiqTech International, Inc., a Nevada corporation, is a clean technology company that provides state-of-the-art ceramic silicon carbide filtration technologies for gas and liquid purification. LiqTech's silicon carbide membranes are designed to be used in the most challenging purification applications, and its silicon carbide filters are used to control diesel exhaust soot emissions. Using nanotechnology, LiqTech develops products using its proprietary silicon carbide technology, resulting in a wide range of component membranes, membrane systems, and filters for both microfiltration and ultrafiltration applications. By incorporating LiqTech's SiC liquid membrane technology with the Company's extensive systems design experience and capabilities, LiqTech offers unique, turnkey solutions for the most difficult water purification applications.

COMPANY PROFILES

Market Cap data (\$USD) updated as of 1.24.23

LIVEWORLD, INC. (OTC PINK: LVWD)

Technology | Market Cap: \$1M

LiveWorld is a digital agency specializing in social media and technology solutions that help companies spark emotional conversations, build stronger customer relationships, and drive behavior change. We live at the intersection of bold creative rooted in strategy that inspires, moderation that activates human interactions, and technology that enriches and scales customer experiences. With over 25 years of making connections, our integrated team leverages our social media DNA to deliver emotion driven behavior change through digital campaigns with a human touch. LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in San Jose, California, with an additional office in New York City.

MANNKIND CORPORATION (NASDAQ: MNKD)

Healthcare | Market Cap: \$1.3B

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

MOGO INC. (TSX: MOGO / NASDAQ: MOGO)

FinTech | Market Cap: \$60M

Mogo Inc., one of Canada's leading financial technology companies, is empowering its 1.9 million members with simple digital solutions to help them get in control of their financial health while also making a positive impact with their money. Through the free Mogo app, consumers can access a digital spending account with Mogo Visa® Platinum Prepaid Card featuring automatic carbon offsetting, easily buy and sell bitcoin, get free monthly credit score monitoring and ID fraud protection and access personal loans and mortgages. Mogo's new MogoTrade app offers commission-free stock trading that helps users make a positive impact with every investment and together with Moka, Mogo's wholly-owned subsidiary bringing automated, fully-managed flat-fee investing to Canadians, forms the heart of Mogo's digital wealth platform. Mogo's wholly-owned subsidiary, Carta Worldwide, also offers a digital payments platform that powers the next-generation card programs from innovative fintech companies in Europe, North America and APAC.

NORTHERN TECHNOLOGIES INTERNATIONAL CORPORATION (NASDAQ: NTIC)

Basic Materials | Market Cap: \$121M

Northern Technologies International Corporation develops and markets proprietary, environmentally beneficial products and services in over 60 countries either directly or via a network of subsidiaries, joint ventures, independent distributors and agents. NTIC's primary business is corrosion prevention marketed mainly under the ZERUST® brand. NTIC has been selling its proprietary ZERUST® rust and corrosion inhibiting products and services to the automotive, electronics, electrical, mechanical, military and retail consumer markets for almost 50 years and more recently, has also expanded into the oil and gas industry. NTIC offers worldwide on-site technical consulting for rust and corrosion prevention issues. NTIC's technical service consultants work directly with the end users of NTIC's products to analyze their specific needs and develop systems to meet their technical requirements. NTIC also markets and sells a portfolio of bio-based and biodegradable polymer resin compounds and finished products marketed under the Natur-Tec® brand.

ONESOFT SOLUTIONS INC. (TSXV: OSS / OTCQB: OSSIF)

Technology | Market Cap: \$49M

OneSoft has developed software technology and products that have capability to transition legacy, on-premises licensed software applications to operate on the Microsoft Azure Cloud Platform. Our business strategy is to seek opportunities to incorporate Data Science and Machine Learning, business intelligence and predictive analytics to create cost-efficient, subscription-based software-as-a-service solutions. Visit www.onesoft.ca for more information. OneSoft's wholly owned subsidiary, OneBridge Solutions Canada Inc., develops and markets revolutionary new SaaS solutions that use advanced Data Sciences and Machine Learning to analyze big data using predictive analytics to assist Oil & Gas pipeline operators to predict pipeline failures and thereby save lives, protect the environment, reduce operational costs, and address regulatory compliance requirements. Visit www.onebridgesolutions.com for more information.

ONE STOP SYSTEM (NASDAQ: OSS)

Technology | Market Cap: \$66M

One Stop Systems, Inc. (Nasdaq: OSS) is a global leader in AI Transportable solutions for the demanding 'edge.' It designs and manufactures the highest performance compute and storage products that enable autonomous and artificial intelligence (AI) capabilities without compromise. These hardware and software platforms bring the latest data center performance to the harsh and challenging applications, whether they are on land, sea or in the air. OSS products include ruggedized servers, compute accelerators, flash storage arrays, and storage acceleration software. These specialized compact products are used across multiple industries and applications, including autonomous trucking and farming, as well as aircraft, drones, ships and vehicles within the defense industry. OSS solutions address the entire AI workflow, from high-speed data acquisition to deep learning, training and large-scale inference, and have delivered many industry firsts for industrial OEM and government customers. As the fastest growing segment of the multi-billion-dollar edge computing market, AI Transportables require—and OSS delivers—the highest level of performance in the most challenging environments without compromise. OSS products are available directly or through global distributors. For more information, go to www.onestopsystems.com. You can also follow OSS on Twitter, YouTube, and LinkedIn.

COMPANY PROFILES

Market Cap data (\$USD) updated as of 1.24.23

OPSENS INC. (TSX: OPS / OTCQX: OPSSF)

Healthcare | Market Cap: \$173M

OpSens Inc. (TSX: OPS) (OTCQX: OPSSF) a cardiology medical device company providing innovative product solutions based on its patented optical technology, focuses mainly on coronary artery stenosis measurement in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 150,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada. OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

PERIMETER MEDICAL IMAGING (TSXV: PINK / PINK: PYNKF)

Healthcare | Market Cap: \$83M

With headquarters in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company that is driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month, underscoring the company's dedication to helping surgeons, radiologists, and pathologists use Perimeter's imaging technology and AI in the fight against breast cancer, which is estimated to account for 30% of all female cancer diagnoses this year.

PETVIVO HOLDINGS INC. (NASDAQ: PETV)

Healthcare | Market Cap: \$24M

PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.

PRECISION OPTICS CORPORATION (NASDAQ: POCI)

Healthcare | Market Cap: \$33M

Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power.

QUIPT HOME MEDICAL (NASDAQ: QUIPT / TSXV: QUIPT)

Healthcare | Market Cap: \$220M

Quipt Home Medical provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company's organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services and making life easier for the patient.

RELIQ HEALTH TECHNOLOGIES INC. (TSXV: RHT / PINK: RQHTF)

Healthcare | Market Cap: \$81M

Reliq Health Technologies is a rapidly growing global healthcare technology that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq's powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the WKN as A2AJTB.

COMPANY PROFILES

Market Cap data (\$USD) updated as of 1.24.23

REVIVA PHARMACEUTICALS HOLDINGS (NASDAQ: RVPH)

Healthcare | Market Cap: \$86M

Reviva Pharmaceuticals Holdings is a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity.

S&W SEED COMPANY (NASDAQ: SANW)

Industrials | Market Cap: \$63M

Founded in 1980, S&W Seed Company is a global integrated seed technology company focused on middle market crops. Headquartered in the United States and with operations in Australia, S&W's vision is to be the world's preferred proprietary seed Company which supplies a range of forage and specialty crop products that supports the growing global demand for animal proteins and healthier consumer diets. S&W is a global leader in proprietary alfalfa, sorghum and pasture seeds, with significant research and development, production and distribution capabilities. S&W's product portfolio also includes hybrid sunflower and wheat and the company is utilizing its research and breeding expertise to develop and produce stevia, the all-natural, zero calorie sweetener for the food and beverage industry.

SCIENTIFIC INDUSTRIES, INC. (OTCQB:SCND)

Healthcare | Market Cap: \$34M

Scientific Industries (OTCQB:SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems under the product name Cell Growth Quantifier and Liquid Injection System. Scientific Industries' products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit www.scientificindustries.com. Scientific Bioprocessing, Inc. ("SBI") is dedicated to providing state-of-the-art instruments, strategies, and technologies to expedite the production of viable cells and therapies with a streamlined process and product consistency. SBI's mission is to develop sensor technologies and instruments that make cell culture and bioprocessing work easier, experiments more reproducible, and culture conditions better suited to meet experimental objectives. SBI is a subsidiary of Scientific Industries Holdings, Inc. To learn more, visit www.scientificbio.com.

SENESTECH (NASDAQ: SNES)

Industrials | Market Cap: \$3M

SenesTech is "The Pest Control Difference" for the 21st century. They are rodent fertility control specialists fueled by our passion to create a healthy environment by virtually eliminating rodent pest populations. We keep an inescapable truth in mind. Two rats can be responsible for the birth of up to 15,000 pups a year. SenesTech invented ContraPest®, the world's first and only U.S. EPA registered rodent contraceptive. ContraPest® fits seamlessly into all integrated pest management programs, greatly improving the overall goal of effective rodent management. We strive for clean cities, efficient businesses and happy households—all through non-lethal, proactive pest control. At SenesTech, they don't just eliminate rats. They make a better world.

SENSUS HEALTHCARE (NASDAQ: SRTS)

Healthcare | Market Cap: \$153M

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, including aesthetic lasers and its needleless TransDermal Infusion System™, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world. For more information, visit www.sensushealthcare.com.

SHUTTLE PHARMACEUTICALS, INC. (NASDAQ: SHPH)

Healthcare | Market Cap: \$31M

Shuttle Pharmaceuticals, Inc. (Shuttle Pharma) is a pre-revenue, clinical-stage pharmaceutical biotech with a focus on developing therapeutics and diagnostics to improve the outcomes of cancer treatment with radiation therapy. The Company's portfolio includes clinical stage radiation sensitizer drugs, predictive biomarkers of radiation response, stimulators of post-RT immunotherapy and cellular reagents for prostate cancer health disparities studies. The lead clinical radiation sensitizing drug, Ropidoxuridine, has reached Phase II clinical development for treatment of glioblastoma brain tumors, an orphan disease indication.

COMPANY PROFILES

Market Cap data (\$USD) updated as of 1.24.23

SOBR SAFE, INC. (NASDAQ: SOBR)

Healthcare | Market Cap: \$16M

The annual cost of alcohol abuse in the U.S. is \$249 billion. Nearly half of all industrial accidents with injuries are alcohol-related, and 1-in-10 U.S. commercial drivers test positive for alcohol (the highest rate worldwide). In response, Denver-based SOBRsafe™ has developed a proprietary, touch-based identity verification, alcohol detection and cloud-based reporting system. The technology is transferable across innumerable form factors, including stationary access control, personal wearables and for telematics integration. A preventative solution in historically reactive industries, it is being deployed for commercial fleets, workplaces and alcohol rehabilitation; other intended applications include probation management and young drivers. This patent-pending alcohol detection solution helps prevent an intoxicated worker from taking the factory floor or a driver from receiving the keys to a truck, bus or rideshare vehicle. An offender is immediately flagged, and an administrator is empowered to take the appropriate corrective actions. At SOBRsafe, we are creating a culture of prevention.

SPOK HOLDINGS, INC. (NASDAQ: SPOK)

Healthcare | Market Cap: \$163M

Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Alexandria, Virginia, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on Spok Care Connect® platforms to enhance workflows for clinicians and support administrative compliance. Our customers send over 100 million messages each month through their Spok® solutions. When seconds count and patients' lives are at stake, Spok enables smarter, faster clinical communication. For more information, visit spok.com or follow @spoktweets on Twitter. Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.

TRELLUS HEALTH PLC (AIM: TRLS)

Healthcare | Market Cap: \$16M

Trellus Health is commercializing the provision of digital chronic condition management solutions for employers and health plans that utilize the scientifically validated GRITT™ resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate™ to coordinate and deliver personalized care remotely via telehealth. The Company is initially focused on Inflammatory Bowel Diseases ("IBD"), which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis but considers its approach to have potential utility and demand across many chronic conditions. The TrellusElevate™ platform is the Company's proprietary connected health platform that incorporates the GRITT™ methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than five years. The GRITT™ methodology and resilience-driven multidisciplinary care model have been scientifically validated to demonstrate meaningful improvements in patient outcomes and over 85 per cent. reduction in unplanned healthcare utilization (emergency department visits and hospitalizations) which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers.

VOLITIONRX (NYSE AMERICAN: VNRX)

Healthcare | Market Cap: \$154M

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring. Volition's research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London, and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market. For more information about Volition, visit Volition's website volition.com.

VOX ROYALTY CORP. (TSXV: VOX / OTCQX: VOXCF)

Basic Materials | Market Cap: \$102M

Vox is a returns focused precious metals royalty company with a portfolio of over 50 royalties and streams spanning eight jurisdictions. The Company was established in 2014 and has since built unique intellectual property, a technically focused transactional team and a global sourcing network which has allowed Vox to target the highest return on invested capital in the royalty sector. Since the beginning of 2020, Vox has announced over 20 separate transactions to acquire over 50 royalties.

ZOMEDICA (NYSE AMERICAN: ZOM)

Healthcare | Market Cap: \$264M

Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.

ZOOM TECHNOLOGIES (TSXV: ZOMD / OTC: ZMDTF)

Technology | Market Cap: \$13M

Zoomd offers a site search engine to publishers, and a mobile app user acquisition platform, integrated with a majority of global digital media, to advertisers. The platform unifies more than 600 media sources into one unified dashboard. Offering advertisers, a user acquisition control center for managing all new customer acquisition campaigns using a single platform. By unifying all these media sources onto a single platform, Zoomd saves advertisers significant resources that would otherwise be spent consolidating data sources, thereby maximizing data collection and data insights while minimizing the resources spent on the exercise. Further, Zoomd is a performance-based platform that allows advertisers to advertise to the relevant target audiences using a key performance indicator-algorithm that is focused on achieving the advertisers' goals and targets.

DISCLAIMERS / DISCLOSURES

Services: Lytham Partners, LLC ("Lytham") provides a range of investor relations services to its clients. The particular services provided vary by client and may change from time to time. Compensation Information: Lytham is compensated by its clients for providing investor relations services. Click here for full compensation information: <https://lythampartners.com/disclosures/>. No Investment Advice: Lytham is not a registered broker-dealer, registered investment adviser or financial adviser, nor does it hold itself out to be. All materials presented on Lytham's website and/or publications or presentations released by Lytham to the public through its website, email, or any other means of transmission are not to be regarded as investment advice, do not constitute an endorsement of the company, and are only for informative purposes. Before making a purchase or sale of any securities mentioned in Lytham's publications or presentations or on its website, Lytham strongly encourages and recommends consultation with a registered securities representative. Lytham's website and/or publications or presentations released by Lytham to the public through its website, email, or any other means of transmission do not constitute an offer to purchase or sell securities, and is not to be construed as a representation of an offer or a solicitation of any offer by Lytham or its client companies to purchase or sell any security. Lytham or any of its affiliates, members, employees, clients, officers, directors, and/or their respective families may from time to time purchase or sell, as agents or principals, or otherwise hold positions in, securities of its client companies, and are free to buy or sell those positions at will. Any such positions may be increased or decreased from time to time in the future without notice. Any information or opinions expressed on Lytham's website and/or publications or presentations released by Lytham are subject to change without notice. Lytham's full disclaimer/disclosures statement can be found on its website at <https://lythampartners.com/disclosures/>.

